Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Glargine vs NPH vs Detemir in T2DM
NCT00941148Phase 4Completed
- Sponsor
- ikfe CRO
- Start
- Apr 2008
- Primary completion
- Mar 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by ikfe CRO. Primary endpoint: Postprandial dynamics of intact proinsulin secretion after standardized test meals (AUC for two hours after dinner) at 12 weeks. Started Apr 2008; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00941148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00941148.